Food Effects of Single Oral Dose of 600mg TR-701

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)12 enrolled

Overview

This is an evaluation of the safety, tolerance, and pharmacokinetics of single oral doses of TR-701 given to normal, healthy, adult volunteers in the fed and fasted state.

Subjects will receive the following treatments in a crossover design: Treatment A: Three 200-mg capsules (600-mg dose) of TR-701 administered orally with 240 mL room temperature tap water after at least a 10-hour fast. Treatment B: Three 200-mg capsules (600-mg dose) of TR-701 administered orally with 240 mL room temperature tap water following a high-fat meal preceded by at least a 10-hour fast. Descriptive statistics will be calculated for PK parameters where available, including Cmax, Tmax, AUC0-t, and AUC0-inf. Minimum, maximum, mean, and median values will be determined and standard deviations will be calculated. Where data are available, food effect will be examined between test (fed state) and reference (fasted state) groups.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Healthy

Interventions

TR-701 600mgDRUG

TR-701 600mg

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * BMI of 20 to 29.9 kg/m2 * Females must be either postmenopausal for at least 1 year, surgically sterile for at least 90 days, or agree to use an acceptable method of birth control Exclusion Criteria: * history or clinical manifestations of any clinically significant medical disorder * history of hypersensitivity or allergies to any drug compound * history of stomach or intestinal surgery or resection * history of alcoholism or drug addiction within 1 year * pregnancy, lactation, or breastfeeding * use of any tobacco-containing or nicotine-containing products within 6 months * use of any other medications * use of alcohol-containing, grapefruit-containing, or caffeine-containing foods or beverages; or foods or beverages with high levels of tyramine

Locations (1)

Covance CRU

San Diego, California, United States

Outcomes

Primary Outcomes

To determine the safety and tolerability of TR-701 600mg given as a single oral dose.

Time frame: 4 days

Secondary Outcomes

To evaluate the pharmacokinetics of single doses of TR-701 and its microbiologically active moiety, TR-700, in healthy adult volunteers in the fed and fasted state

Time frame: 4 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.